Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Horizon Pharma (HZNP) Soars: Stock Adds 10.5% in Session

Horizon Pharma Public Limited Company (HZNP) was a big mover last session, as the company saw its shares rise nearly 11% on the day amid huge volumes.

HZNP : 13.31 (+1.29%)
ALXN : 133.40 (-0.91%)
Seattle Genetics' Adcetris Granted Priority Review by FDA

Seattle Genetics, Inc.'s (SGEN) supplemental Biologics License Application for Adcetris in patients with cutaneous T-cell lymphoma has been accepted by the FDA and granted priority review.

SGEN : 46.30 (-0.15%)
REGN : 467.98 (+0.85%)
SNY : 48.19 (+0.23%)
ALXN : 133.40 (-0.91%)
Novo Nordisk's Semaglutide Shows Remarkable Results in Study

Novo Nordisk (NVO) pipeline candidate shows superior glucose control and weight loss in study in diabetes patients compared with Eli Lilly and Co's Trulicity (dulaglutide).

NVO : 45.18 (-0.35%)
LLY : 77.07 (-0.94%)
REGN : 467.98 (+0.85%)
ALXN : 133.40 (-0.91%)
Spectrum (SPPI) Initiates Phase II Study for Cancer Drug

Spectrum Pharmaceuticals, Inc. (SPPI) initiated the registrational phase III study of qapzola in patients with non-muscle invasive bladder cancer (NMIBC) as per the FDA's requirement.

SPPI : 9.40 (-0.53%)
REGN : 467.98 (+0.85%)
SNY : 48.19 (+0.23%)
ALXN : 133.40 (-0.91%)
Shire Files Marketing Application for Lifitegrast in Europe

Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.

AGN : 223.99 (-0.35%)
SHPG : 145.55 (-1.62%)
SNY : 48.19 (+0.23%)
ALXN : 133.40 (-0.91%)
Alexion Pharm Rises 1.36% on Heavy Volume: Watch For Potential Pullback

Alexion Pharm (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $135.29 to a high of $137.61. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of...

ALXN : 133.40 (-0.91%)
MiMedx Group (MDXG) in Focus: Stock Moves 6.1% Higher

MiMedx Group (MDXG) was a big mover last session, as the company saw its rise over 6% on the day amid huge volumes.

MDXG : 16.52 (+2.55%)
ALXN : 133.40 (-0.91%)
Alexion Receives Three New U.S. Patents for Soliris(R) (eculizumab), Extending Patent Protection Into 2027

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patents No. 9,732,149; 9,718,880; and 9,725,504, which...

ALXN : 133.40 (-0.91%)
Alexion Pharm Up 25.8% Since SmarTrend Uptrend Call (ALXN)

SmarTrend identified an Uptrend for Alexion Pharm (NASDAQ:ALXN) on June 12th, 2017 at $106.88. In approximately 2 months, Alexion Pharm has returned 25.77% as of today's recent price of $134.42.

ALXN : 133.40 (-0.91%)
Regeneron vs. Alexion: Which Stock is a Better Pick Post Q2 Earnings?

Biotech companies, Regeneron (REGN) and Alexion, both topped estimates in Q2 and raised their outlook. But, which stock is better-positioned for the second half of the year?

REGN : 467.98 (+0.85%)
ALXN : 133.40 (-0.91%)
Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3%

Editas Medicine, Inc. (EDIT) moved big moved last session, as its shares rose over 11% on the day.

EDIT : 17.83 (-5.16%)
ALXN : 133.40 (-0.91%)
Forget Teva (TEVA), Buy These 4 Drug Stocks Instead

With generic drugmakers like Teva (TEVA) under pressure, here is a look at four drug stocks that look well-positioned.

GILD : 72.11 (-0.32%)
TEVA : 17.30 (+1.17%)
REGN : 467.98 (+0.85%)
SNY : 48.19 (+0.23%)
ALXN : 133.40 (-0.91%)
Implied Volatility Surging for Alexion Pharmaceuticals (ALXN) Stock Options

Investors need to pay close attention to Alexion Pharmaceuticals (ALXN) stock based on the movements in the options market lately.

ALXN : 133.40 (-0.91%)
Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus

Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q2. Shares were down in after-hours trading.

PBYI : 79.75 (-1.18%)
RHHBY : 31.2300 (-0.98%)
REGN : 467.98 (+0.85%)
ALXN : 133.40 (-0.91%)
Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up

Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.

JNJ : 132.63 (-0.31%)
GERN : 2.03 (-1.46%)
REGN : 467.98 (+0.85%)
ALXN : 133.40 (-0.91%)
Alexion and Sema4 Partner in Rare Disease Diagnostics and Systems Biology

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Sema4 today announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease...

ALXN : 133.40 (-0.91%)
Forget Bayer, Buy These 3 Drug Stocks Instead

With Bayer (BAYRY) reporting mixed results in the second quarter and lowering its outlook, here is a look at 3 drug stocks which look well positioned.

BAYRY : 126.8200 (+0.55%)
GILD : 72.11 (-0.32%)
SNY : 48.19 (+0.23%)
ALXN : 133.40 (-0.91%)
Dynavax Technologies (DVAX) Catches Eye: Stock Adds 11.2% in Session

Dynavax Technologies Corporation (DVAX) was a big mover last session, as the company saw its shares rise over 11% on the day.

DVAX : 16.20 (-1.22%)
ALXN : 133.40 (-0.91%)
BUYINS.NET: ALXN SqueezeTrigger Price is $138.16. There is $552,815,836 That Short Sellers Still Need To Cover.

BUYINS.NET / www.buyins.net is monitoring Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in real time and just received an alert that ALXN is crossing above its primary SqueezeTrigger Price, the price that...

ALXN : 133.40 (-0.91%)
Shares of ALXN Up 29.4% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Alexion Pharm (NASDAQ:ALXN) on June 12th, 2017 at $106.88. In approximately 2 months, Alexion Pharm has returned 29.43% as of today's recent price of $138.33.

ALXN : 133.40 (-0.91%)

Van Meerten Stock Picks

5 Mid Cap Picks
Today I wanted to find 5 Mid Cap Stocks with current momentum, so I used Barchart to sort the S&P 400 Mid Cap Index stocks first for the highest Weighted Alpha, then again for technical buy signal s of 80% or more.
CGNX +0.26 , IPGP +0.85 , NVR -66.19 , TTWO +1.13 , AAN +0.10
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Sep E-mini S&Ps ( ESU17 -0.05% ) this morning are little change, up +0.01%, as stock prices stabilize following Thursday's plunge to a 5-week low. The markets remain on edge about whether President Trump will be... Read More

Chart of the Day

Chart of the Day

Health Insurance Innovations (HIIQ) is the Barchart Chart of the Day.  The health insurance company has a Trend Spotter buy signal, a Weighted Alpha of 341.00+ and gained 538.73% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed Friday with most contracts 1 1/4 to 1 3/4 higher. Nearby Sep lost 2.43% on the week.  Friday’s Commitment of Traders report indicated managed money backing off their net long position by another 27,271 contracts in corn...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.